en · de · es · fr · pt
faq-desk.peptides1126.com › Faq › Regulation And Detection — Beginner to Advanced

Regulation And Detection — Beginner to Advanced

By Editorial Desk · published 2025-07-16 · last reviewed 2025-08-24 · Faq

A practical reference on Nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-08-24 and is reviewed periodically as new material appears.

Regulation and Detection

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Cardarine at a glance

PropertyValueNotes
Regulatory statusProhibited in sport; not approved as medicineListed by WADA at all times.
Common synonymsGW501516, GW-501516, endurobolCardarine is a colloquial name.
Typical analytical methodLC-MS/MSDetects parent compound and metabolites.
Common test matrixUrineBlood and dried blood spots also possible.
Legal classificationVaries by countryOften treated as unapproved drug or research chemical.

Regulation and Analytical Detection

Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.

Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.

Related pages on this site

Background and Regulatory Status

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine as Investigational PPARδ Agonist

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Notes from published material

== Further reading == Scanga R, Scalise M, Marino N, Parisi F, Barca D, Galluccio M, et al. (October 2023). "LAT1 (SLC7A5) catalyzes copper(histidinate) transport switching from antiport to uniport mechanism". iScience. 26 (10) 107738. Bibcode:2023iSci...26j7738S. doi:10.1016/j.isci.2023.107738. PMC 10492218. PMID 37692288.

Andrés de Santa Cruz, who would have had apparent contradictions in his geopolitical projects, due to a highland nationalism, in which he wanted both the reunification of Upper and Lower Peru (in a similar way to the Inca Empire or the Viceroyalty of Peru) as well as to consider dividing Peru into 2 states, one from the north and the other from the south, for the benefit of Bolivia's interests (in addition to recovering the territory of Arica for the benefit of Bolivia), which he envisioned as the "Macedonia of America" and which should have a leadership in the continent, to the detriment of the historical preponderance of Lima and Cuzco as poles of power."When he felt strong, his dreams of power were those of those legendary Incas who descended from the mountains to bring peace, order, and progress to the coast. Then he opened himself to the ideal of 'pan-Peru', of Greater Peru. Bolivia would be the "Macedonia of America". If they beat and humiliated him and cornered him on the plateau, he wanted, not so much for revenge as for security reasons, next to Bolivia, a divided or impotent Peru. His maximum program was a strong Greater Peru and extensive, that is, the Confederation, with him as head. His minimum program was to govern Bolivia, but, at his side, the bifurcation of Peru into two states and the possible fall of the South State under Bolivia's sphere of influence Such is the explanation of his political behavior until 1839.

== Academic programs == Certified Nursing Assistant (CNA) Phlebotomy Technician Medical Laboratory Assistant (MLA) Patient Care Technician Certified Caregiver Assisted Living Facility Manager CPR First Aide Continuing Education for Assisted Living Caregivers and Managers

Sources: en.wikipedia.org

Further detail

Sexual dysfunction, including loss of libido, erectile dysfunction, lack of vaginal lubrication, and anorgasmia, are some of the most commonly encountered adverse effects of treatment with fluoxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%. In 2019, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that packaging leaflets of selected SSRIs and SNRIs should be amended to include information regarding a possible risk of persistent sexual dysfunction. Following on the European assessment, a safety review by Health Canada "could neither confirm nor rule out a causal link ... which was long lasting in rare cases", but recommended that "healthcare professionals inform patients about the potential risk of long-lasting sexual dysfunction despite discontinuation of treatment".

University-based ophthalmologists in the US and Canada further refined the use of botulinum toxin as a therapeutic agent. By 1985, a scientific protocol of injection sites and dosage had been empirically determined for treatment of blepharospasm and strabismus. Side effects in treatment of this condition were deemed to be rare, mild and treatable. The beneficial effects of the injection lasted only four to six months. Thus, blepharospasm patients required re-injection two or three times a year. In 1986, Scott's micromanufacturer and distributor of Botox was no longer able to supply the drug because of an inability to obtain product liability insurance. People became desperate, as supplies of Botox were gradually consumed, forcing him to abandon people who would have been due for their next injection. For a period of four months, American blepharospasm patients had to arrange to have their injections performed by participating doctors at Canadian eye centers until the liability issues could be resolved. In December 1989, Botox was approved by the US FDA for the treatment of strabismus, blepharospasm, and hemifacial spasm in people over 12 years old. In the case of treatment of infantile esotropia in people younger than 12 years of age, several studies have yielded differing results.

1984: Ong Hwee Kuan, Ong Chin Hock and Yeo Ching Boon were hanged on 24 February 1984 for the robbery, kidnapping and murder of a policeman, Lee Kim Lai, on 25 April 1978. The trio were also responsible for the murder of a taxi driver Chew Theng Hin on the same night Lee was killed. 1986: Sim Min Teck, one of the three perpetrators of the 1980 Jurong fishing port murders, which he committed when he was 18. He was sentenced to death for murder in March 1985 and lost his appeal in July 1986, before he was hanged. 1988: Adrian Lim, Tan Mui Choo, and Hoe Kah Hong, the three perpetrators of the 1981 Toa Payoh ritual murders, were hanged on 25 November 1988. 1988: Sek Kim Wah, a Singaporean military conscript and serial killer who committed the 1983 Andrew Road triple murders and another double murder near Seletar Road, was hanged on 9 December 1988. As of 2024, Sek Kim Wah remains as Singapore's first and only serial killer to date, with 5 victims. 1990: Michael Tan Teow and Lim Beng Hai, the two unemployed Singaporeans and drug abusers who killed a housewife and two children to steal their money to buy drugs. Both were eventually charged with murder, convicted and sentenced to hang. Before his execution however, Tan committed suicide in May 1990, therefore, only Lim was put to death on 5 October 1990. 1992: Hensley Anthony Neville, a Eurasian Singaporean found guilty of the 1984 rape and murder of 19-year-old Lim Hwee Huang. He fled to Malaysia after killing Lim, but was caught in March 1987 and hanged on 28 August 1992 after a six-day trial hearing.

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine legal?

Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.

How is cardarine detected in athletes?

Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.

Is cardarine a SARM?

No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Network